107 related articles for article (PubMed ID: 7749386)
1. Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.
Linz W; Wiemer G; Schölkens BA
Braz J Med Biol Res; 1994 Aug; 27(8):1949-54. PubMed ID: 7749386
[TBL] [Abstract][Full Text] [Related]
2. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors.
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Pharmacol Rev; 1995 Mar; 47(1):25-49. PubMed ID: 7784479
[TBL] [Abstract][Full Text] [Related]
3. [Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].
Linz W; Wiemer G; Gohlke P; Unger T; Schölkens BA
Z Kardiol; 1994; 83 Suppl 4():53-6. PubMed ID: 7856280
[TBL] [Abstract][Full Text] [Related]
4. Role of kinins in the pathophysiology of myocardial ischemia. In vitro and in vivo studies.
Linz W; Wiemer G; Schölkens BA
Diabetes; 1996 Jan; 45 Suppl 1():S51-8. PubMed ID: 8529801
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.
Linz W; Wiemer G; Schaper J; Zimmermann R; Nagasawa K; Gohlke P; Unger T; Schölkens BA
Mol Cell Biochem; 1995 Jun 7-21; 147(1-2):89-97. PubMed ID: 7494560
[TBL] [Abstract][Full Text] [Related]
6. Local inhibition of bradykinin degradation in ischemic hearts.
Linz W; Martorana PA; Schölkens BA
J Cardiovasc Pharmacol; 1990; 15 Suppl 6():S99-109. PubMed ID: 1697370
[TBL] [Abstract][Full Text] [Related]
7. Contribution of bradykinin to the cardiovascular effects of ramipril.
Linz W; Wiemer G; Schölkens BA
J Cardiovasc Pharmacol; 1993; 22 Suppl 9():S1-8. PubMed ID: 7514234
[TBL] [Abstract][Full Text] [Related]
8. Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.
Nolly H; Miatello R; Damiani MT; Abate CD
Immunopharmacology; 1997 Jun; 36(2-3):185-91. PubMed ID: 9228545
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.
Gohlke P; Linz W; Schölkens BA; Kuwer I; Bartenbach S; Schnell A; Unger T
Hypertension; 1994 Apr; 23(4):411-8. PubMed ID: 8144208
[TBL] [Abstract][Full Text] [Related]
10. The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.
Hartman JC
Ann Thorac Surg; 1995 Sep; 60(3):789-92. PubMed ID: 7545893
[TBL] [Abstract][Full Text] [Related]
11. Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.
Linz W; Gohlke P; Unger T; Schölkens BA
Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():31-4. PubMed ID: 7646309
[TBL] [Abstract][Full Text] [Related]
12. The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.
Dumoulin MJ; Adam A; Burnett J; Heublein D; Yamaguchi N; Lamontagne D
Can J Physiol Pharmacol; 2005 Feb; 83(2):166-73. PubMed ID: 15791290
[TBL] [Abstract][Full Text] [Related]
13. ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.
Linz W; Wiemer G; Schölkens BA
J Mol Cell Cardiol; 1992 Aug; 24(8):909-19. PubMed ID: 1331474
[TBL] [Abstract][Full Text] [Related]
14. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.
Linz W; Schölkens BA
Br J Pharmacol; 1992 Apr; 105(4):771-2. PubMed ID: 1324047
[TBL] [Abstract][Full Text] [Related]
15. Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.
Rhaleb NE; Yang XP; Scicli AG; Carretero OA
Hypertension; 1994 Jun; 23(6 Pt 2):865-8. PubMed ID: 7515854
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin-converting enzyme inhibitors unmask endogenous kinin production by bovine coronary artery endothelium.
Hecker M; Bara AT; Busse R
Eur Heart J; 1993 Nov; 14 Suppl I():161-3. PubMed ID: 8293768
[TBL] [Abstract][Full Text] [Related]
17. [Reduction of infarct size and remodeling after ramipril].
Martorana PA; Linz W; Schölkens BA
Z Kardiol; 1994; 83 Suppl 4():63-4. PubMed ID: 7856282
[TBL] [Abstract][Full Text] [Related]
18. Endothelium-derived bradykinin: implications for angiotensin-converting enzyme-inhibitor therapy.
Busse R; Fleming I; Hecker M
J Cardiovasc Pharmacol; 1993; 22 Suppl 5():S31-6. PubMed ID: 7508049
[TBL] [Abstract][Full Text] [Related]
19. Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.
Liu YH; Yang XP; Sharov VG; Sigmon DH; Sabbath HN; Carretero OA
Hypertension; 1996 Jan; 27(1):7-13. PubMed ID: 8591891
[TBL] [Abstract][Full Text] [Related]
20. The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.
Martorana PA; Schölkens BA
Agents Actions Suppl; 1992; 38 ( Pt 3)():98-102. PubMed ID: 1462888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
